Literature DB >> 2787931

The cost of prostatic cancer in a defined population.

P Carlsson1, H Hjertberg, B Jönsson, E Varenhorst.   

Abstract

Health-service costs for prostatic adenocarcinoma were calculated on the basis of 101 patients resident in the Linköping area throughout their illness and who died in 1984-1985. At the time of diagnosis 54 tumours were advanced and 47 were localized. Primary treatment was expectant or surgical in 77 and oestrogen therapy in 17 cases. The average number of life-years lost was 4.3 in the total series and 10.7 in the men younger than 70. The median cost per case, SEK 50,000 (US dollars 7,900), was significantly lower than the average cost, SEK 79,000 (US dollars 12,400), due to a few high-cost patients. Approximately 50% of the total treatment cost was incurred during the year before death. The total number of hospitalizations for prostatic cancer in Sweden during 1984 was 11,800. The total estimated cost of this disease for the Swedish Health Services in 1985 was around 300 million SEK (47 million US dollars).

Entities:  

Mesh:

Year:  1989        PMID: 2787931     DOI: 10.3109/00365598909180819

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  7 in total

1.  Prostate cancer: 12. The economic burden.

Authors:  S A Grover; H Zowall; L Coupal; M D Krahn
Journal:  CMAJ       Date:  1999-03-09       Impact factor: 8.262

2.  Pharmacoeconomic aspects in the treatment of curable and incurable cancer.

Authors:  V Jønsson; S R Clausen; M M Hansen
Journal:  Pharmacoeconomics       Date:  1995-10       Impact factor: 4.981

3.  Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.

Authors:  M D Krahn; A Coombs; I G Levy
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

Review 4.  Comparison of the cost-effectiveness of various therapies for common prostatic disorders.

Authors:  E A Amin; M Amin
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

Review 5.  Clinical and economic considerations in the treatment of prostate cancer.

Authors:  E Varenhorst; P Carlsson; K Pedersen
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

Review 6.  The economic costs of early stage prostate cancer.

Authors:  Christopher S Saigal; Mark S Litwin
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 7.  Quality of life and economic considerations in the management of prostate cancer.

Authors:  Marco Turini; Alberto Redaelli; Paola Gramegna; Davide Radice
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.